Spike Protein News and Research

RSS

T cell immunity induced after mild COVID could contribute to protection against re-infection

An interesting new study finds that in both adults and children, a mild infection with the SARS-CoV-2 elicits an antigen-specific memory T-cell response.

20 Sep 2021

What impact has SARS-CoV-2 variant B.1.1.519 had on Mexico City?

The current study reports the effective reproduction number of B.1.1.519 and presents its geographical origin based on phylogenetic analysis.

20 Sep 2021

SARS-CoV-2 antibody models describe differences between the kinetics of different antibodies

Researchers have created kinetic models of IgG and IgM anti-SARS-CoV-2 antibodies over 13.5 months following infection to understand long-lasting immunity better.

20 Sep 2021

Novel spike NTD mutations in SARS-CoV-2 Delta variant associated with increased viral loads and immune evasion

Researchers from the University of Southern California investigated mutations in the N-terminal and RBD domains of the spike protein.

20 Sep 2021

The influence of prior seasonal coronavirus infection on disease severity in COVID-19

A new study posted to the bioRxiv* server attempted to explore anti-spike IgG responses, Fc-gamma receptor (FcγR) activation, IgG targeting of immunodominant regions, and recall responses due to seasonal hCoV infections in non-hospitalized COVID-19 patients.

20 Sep 2021

Characterizing the flexibility of SARS-CoV-2 variant of concern spike proteins

A novel protein modeling method assesses changes to the conformation of the SARS-CoV-2 spike protein that have been encountered by mutation.

19 Sep 2021

A 100% French nasal vaccine against SARS-CoV-2 to move into the clinical phase in 2022

In contrast to intramuscular vaccines, only nasal vaccines are able to block the virus in the nose by inducing local immunity in the nasal mucosa, i.e. the portal of entry and multiplication of the virus.

18 Sep 2021

UW Medicine enrolls volunteers for COVID-19 booster vaccine trial

Researchers at the University of Washington School of Medicine are enrolling volunteers for a COVID-19 booster vaccine trial.

18 Sep 2021

Thousands of vulnerable hospital patients set to benefit from new COVID-19 treatment

Thousands of vulnerable NHS patients in hospital due to COVID-19 are set to benefit from a ground-breaking new antibody treatment, the government has announced today (17 September 2021).

18 Sep 2021

mAb treatment can rapidly select for SARS-CoV-2 resistance, suggests study

A study evaluates the efficacy of a mAb to prevent disease progression in non-hospitalized persons with symptomatic SARS-CoV-2 infection.

17 Sep 2021

Adenovirus-based nanoparticle vaccine elicits potent SARS-CoV-2 neutralizing antibody response

In a study available on the preprint server medRxiv*, researchers have created a vaccine designed to overcome issues associated with attenuated-virus vaccines.

17 Sep 2021

Therapeutic potential of clinical-grade ACE2 for blocking SARS-CoV-2 variants

According to new research by an international team of scientists, all SARS-CoV-2 variants, including variants of concern (VOC) Alpha, Beta, Gamma, and Delta, exhibit enhanced affinity toward recombinant human soluble ACE2.

16 Sep 2021

Evolved SARS-CoV-2 viruses gain higher infectivity and cause more rapid infection spread

Viruses accumulate mutations as they replicate in infected cells. Repeated replication can lead to viral strains that show attenuated virulence. Such strains may act as vaccines if the attenuated virus can produce immunity without serious disease.

16 Sep 2021

Pfizer-BioNTech’s COVID-19 vaccine proves effective against recent SARS-CoV-2 variants

Researchers in the United States and Germany have conducted a study showing that the Pfizer-BioNTech vaccine designed to protect against coronavirus disease 2019 (COVID-19) is effective against recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2).

16 Sep 2021

Spike Protein News and Research

T cell immunity induced after mild COVID could contribute to protection against re-infection

What impact has SARS-CoV-2 variant B.1.1.519 had on Mexico City?

SARS-CoV-2 antibody models describe differences between the kinetics of different antibodies

Novel spike NTD mutations in SARS-CoV-2 Delta variant associated with increased viral loads and immune evasion

The influence of prior seasonal coronavirus infection on disease severity in COVID-19

Characterizing the flexibility of SARS-CoV-2 variant of concern spike proteins

A 100% French nasal vaccine against SARS-CoV-2 to move into the clinical phase in 2022

UW Medicine enrolls volunteers for COVID-19 booster vaccine trial

Thousands of vulnerable hospital patients set to benefit from new COVID-19 treatment

mAb treatment can rapidly select for SARS-CoV-2 resistance, suggests study

Adenovirus-based nanoparticle vaccine elicits potent SARS-CoV-2 neutralizing antibody response

Therapeutic potential of clinical-grade ACE2 for blocking SARS-CoV-2 variants

Evolved SARS-CoV-2 viruses gain higher infectivity and cause more rapid infection spread

Pfizer-BioNTech’s COVID-19 vaccine proves effective against recent SARS-CoV-2 variants

Flavonoids can potentially help prevent COVID-19-induced diarrhea, study finds

Study looks at exposure to different SARS-CoV-2 variants and immune response

COVID mRNA vaccines display weakened immune response with age and diminish over time, according to new study

Phase I trial investigates using antiparasitic nitazoxanide for treatment of COVID-19

SARS-CoV-2 variants show substantial differences in spike structure

Natural SARS-CoV-2 infection induces more durable immunity than vaccination study suggests

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News